verapamil has been researched along with diazepam in 88 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (17.05) | 18.7374 |
| 1990's | 11 (12.50) | 18.2507 |
| 2000's | 20 (22.73) | 29.6817 |
| 2010's | 39 (44.32) | 24.3611 |
| 2020's | 3 (3.41) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Adachi, Y; Sugiyama, Y; Suzuki, H | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Caron, G; Ermondi, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Briand, X; Faller, B; Lázaro, E; Lowe, PJ | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Avdeef, A; Tam, KY | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Barber, S; Dew, TP; Farrell, TL; Poquet, L; Williamson, G | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Deng, Y; Li, Y; Liu, Q; Qiang, X; Sang, Z; Tan, Z; Xiao, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
| Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 2 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Handzlik, J; Jastrzębska-Więsek, M; Kieć-Kononowicz, K; Kucwaj-Brysz, K; Latacz, G; Lubelska, A; Partyka, A; Wesołowska, A | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| Ganeshpurkar, A; Gupta, SK; Gutti, G; Krishnamurthy, S; Kumar, D; Modi, G; Singh, SK | 1 |
| An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Rai, SN; Shankar, S; Sharma, P; Shrivastava, SK; Singh, SP; Srivastava, P; Srivastava, RK; Tripathi, PN | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Fan, X; Liu, W; Sang, Z; Shi, J; Wang, K; Yang, D; Zhang, P; Zhang, Z; Zhu, G | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
| Jaiswal, S; Raja Ayyannan, S; Tiwari, V; Uniyal, A | 1 |
| Short, D | 1 |
| File, SE; Hitchcott, PK; Zharkovsky, A | 1 |
| Baba, A; Matsuda, T; Shimizu, I | 1 |
| Little, HJ | 1 |
| Chugh, Y; Saha, N; Sankaranarayanan, A; Sharma, PL | 1 |
| Sulcová, A | 1 |
| Dadkar, VN; Dhar, HL; Jaguste, VS | 1 |
| Mehmel, HC | 1 |
| Ahlf, SB; Dawson, CA; Gualtieri, JF; Kampine, JP; Kotrly, KJ; Roerig, DL | 1 |
| Forster, P; Stone, TW | 1 |
| Schwartzkroin, PA; Taube, JS | 1 |
| Cohen, G; Dajee, H; Flacke, W; Kapur, PA; Norel, EJ | 1 |
| Dolin, SJ; Halsey, MJ; Little, HJ | 1 |
| Hüter, J; Lammers, G | 1 |
| Bergsjo, P | 1 |
| Hauschild, R; Seewald, HJ | 1 |
| Filias, N; Jornod, J | 1 |
| Both, A | 1 |
| Wheatley, D | 1 |
| Duraković, Z; Gasparović, V; Gjurasin, M; Ivanović, D; Plavsić, F | 1 |
| Contreras, E; Contreras, G; Norris, B; Nunez, G | 1 |
| Fukura, H; Igarashi, M; Komiya, Y | 1 |
| Ara, JR; Castiella, J; Pina, MA; Remírez, A | 1 |
| Cseppentö, A; Kovács, P; Nagy, E; Szabó, JZ; Szentmiklósi, AJ; Ujfalusi, A | 1 |
| Balint, GA | 1 |
| Manley, SW; Mitchell, AM; Mortimer, RH; Powell, KA | 1 |
| Chugun, A; Futamura, K; Hara, Y; Kobayashi, H; Kondo, H; Nishino, T; Ooshiro, S; Temma, K | 1 |
| Cattaneo, S; Cosentino, M; Di Grazia, L; Fietta, AM; Frigo, G; Lecchini, S; Marino, F; Rasini, E | 1 |
| Damron, DS; Kanaya, N; Murray, PA | 1 |
| Axerio-Cilies, P; Bai, YF; Chan, ES; Chiu, M; Connolly, MB; Demos, M; Farrer, MJ; Guella, I; Huh, L; Liu, L; Lu, J; Wang, YT; Xu, ZD | 1 |
| Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N | 1 |
3 review(s) available for verapamil and diazepam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The benzodiazepines: anxiolytic and withdrawal effects.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Carbolines; Diazepam; Disease Models, Animal; Ethanol; Flumazenil; Humans; Rats; Receptors, GABA-A; Substance Withdrawal Syndrome; Verapamil | 1991 |
[Drugs inhibiting contractions].
Topics: Adrenergic beta-Agonists; Calcium; Diazepam; Ethanol; Female; Fetal Diseases; Humans; Meperidine; Metaproterenol; Muscle Contraction; Obstetric Labor Complications; Obstetric Labor, Premature; Pregnancy; Prenylamine; Progesterone; Sympathomimetics; Verapamil | 1973 |
2 trial(s) available for verapamil and diazepam
| Article | Year |
|---|---|
Effects of verapamil and nifedipine on psychomotor performance in human subjects.
Topics: Adult; Blood Pressure; Diazepam; Drug Evaluation; Female; Heart Rate; Higher Nervous Activity; Humans; Male; Nifedipine; Psychomotor Performance; Verapamil | 1991 |
The value of anti-anxiety drugs in the management of cardiac disease.
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Anxiety; Clinical Trials as Topic; Clorazepate Dipotassium; Coronary Disease; Diazepam; Double-Blind Method; Female; Humans; Hypertension; Male; Verapamil | 1982 |
83 other study(ies) available for verapamil and diazepam
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.
Topics: Adenosine Triphosphate; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Caco-2 Cells; Cell Membrane Permeability; Dose-Response Relationship, Drug; Humans; Hydrolysis; LLC-PK1 Cells; Male; Mice; Mice, Knockout; Models, Biological; Pharmaceutical Preparations; Swine; Tissue Distribution; Transfection | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
Topics: Humans; Kinetics; Membranes, Artificial; Permeability; Protein Binding; Serum Albumin | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Cinnamates; Enterocytes; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Kinetics; Models, Biological; Molecular Conformation; Osmolar Concentration; Phenols | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Cognition; Glucuronates; Humans; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
Topics: Dose-Response Relationship, Drug; Humans; Hydantoins; Molecular Structure; Piperazines; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Matrix Metalloproteinase 2; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship | 2018 |
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
Topics: Antioxidants; Benzoxazoles; Cholinesterase Inhibitors; Drug Design; Humans; Learning; Memory; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2019 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Development; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |
Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
Topics: Amidohydrolases; Analgesics; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Monoacylglycerol Lipases; Neuralgia; Semicarbazones | 2022 |
The management of the patient with angina.
Topics: Angina Pectoris; Anticoagulants; Clofibrate; Coronary Artery Bypass; Diazepam; Digoxin; Humans; Isosorbide Dinitrate; Nitroglycerin; Oxprenolol; Perhexiline; Prenylamine; Propranolol; Verapamil | 1977 |
Concurrent treatment with verapamil prevents diazepam withdrawal-induced anxiety, in the absence of altered calcium flux in cortical synaptosomes.
Topics: Animals; Anxiety; Calcium; Calcium Radioisotopes; Cerebral Cortex; Diazepam; Male; Rats; Substance Withdrawal Syndrome; Synaptosomes; Verapamil | 1992 |
Na+ influx-induced decrease of (Na+ + K+)-ATPase activity in rat brain slices: role of Ca2+.
Topics: Amiloride; Animals; Bepridil; Brain; Calcium; Calcium Channel Blockers; Cell Membrane; Chelating Agents; Diazepam; Egtazic Acid; In Vitro Techniques; Kinetics; Male; Monensin; Nifedipine; omega-Conotoxins; Peptides, Cyclic; Quinacrine; Rats; Rats, Inbred Strains; Sodium; Sodium-Potassium-Exchanging ATPase; Verapamil; Veratrine | 1991 |
Effect of peripheral administration of cinnarizine and verapamil on the abstinence syndrome in diazepam-dependent rats.
Topics: Animals; Autonomic Nervous System; Behavior, Animal; Cinnarizine; Diazepam; Female; Male; Motor Activity; Rats; Rats, Inbred Strains; Reflex, Startle; Substance Withdrawal Syndrome; Substance-Related Disorders; Verapamil | 1992 |
Calcium channel blocker verapamil antagonizes anxiolytic effect of diazepam in mice.
Topics: Aggression; Animals; Behavior, Animal; Diazepam; Male; Mice; Verapamil | 1991 |
[Therapy of acute myocardial infarct].
Topics: Acidosis; Analgesics; Atropine; Bicarbonates; Bradycardia; Cardiac Complexes, Premature; Critical Care; Diazepam; Digitalis Glycosides; Early Ambulation; First Aid; Furosemide; Heparin; Humans; Hypertension; Lidocaine; Myocardial Infarction; Nitroglycerin; Pacemaker, Artificial; Positive-Pressure Respiration; Sodium; Sodium Bicarbonate; Verapamil | 1985 |
First-pass uptake of verapamil, diazepam, and thiopental in the human lung.
Topics: Adult; Aged; Chromatography, Gas; Diazepam; Humans; Indocyanine Green; Injections, Intravenous; Lung; Middle Aged; Thiopental; Verapamil | 1989 |
Purine effects on (3H)-clonidine binding to rat brain.
Topics: Animals; Brain; Clonidine; Diazepam; In Vitro Techniques; Kinetics; Male; Phenylisopropyladenosine; Purines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Tritium; Verapamil | 1986 |
Ineffectiveness of organic calcium channel blockers in antagonizing long-term potentiation.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Cinnarizine; Diazepam; Flunarizine; Guinea Pigs; Hippocampus; Neurons; Nifedipine; Nitrendipine; Reaction Time; Synaptic Transmission; Verapamil | 1986 |
Haemodynamic effects of verapamil administration after large doses of fentanyl in man.
Topics: Adult; Aged; Anesthesia, General; Blood Pressure; Coronary Artery Bypass; Coronary Disease; Diazepam; Epinephrine; Fentanyl; Hemodynamics; Humans; Middle Aged; Norepinephrine; Pancuronium; Propranolol; Pulmonary Circulation; Stroke Volume; Vascular Resistance; Verapamil | 1986 |
Calcium channel antagonists decrease the ethanol withdrawal syndrome.
Topics: Animals; Calcium Channel Blockers; Diazepam; Ethanol; Flunarizine; Male; Motor Activity; Nimodipine; Nitrendipine; Pentylenetetrazole; Rats; Rats, Inbred Strains; Seizures; Substance Withdrawal Syndrome; Verapamil | 1986 |
[Beta adrenergic agents as labor inhibitors].
Topics: Administration, Oral; Adrenergic beta-Agonists; Calcium; Diazepam; Ethanol; Female; Half-Life; Humans; Injections, Intramuscular; Injections, Intravenous; Nylidrin; Obstetric Labor, Premature; Oxytocin; Pregnancy; Rest; Verapamil | 1973 |
[Spontaneous motility of the human fallopian tube and pharmacologic effect on it in a in-vitro study].
Topics: Adult; Diazepam; Ethanol; Fallopian Tubes; Female; Humans; In Vitro Techniques; Manometry; Middle Aged; Muscle Contraction; Muscle Relaxants, Central; Nylidrin; Perfusion; Phenobarbital; Pregnancy; Verapamil | 1974 |
[Cardiovascular complications of tricyclic anti-depressants. Apropos of a case of acute poisoning].
Topics: Adult; Arrhythmias, Cardiac; Bundle-Branch Block; Diazepam; Digitalis Glycosides; Electrocardiography; Female; Furosemide; Humans; Imipramine; Poisoning; Respiration; Seizures; Tachycardia; Verapamil | 1973 |
[Therapy of primary pulmonary hypertension].
Topics: Acetylcholine; Amino Alcohols; Carbachol; Child; Diazepam; Diazoxide; Female; Humans; Hypertension, Pulmonary; Isoproterenol; Isosorbide Dinitrate; Neostigmine; Nitroglycerin; Pentaerythritol Tetranitrate; Rest; Theophylline; Tolazoline; Verapamil | 1970 |
[Simultaneous poisoning with medigoxin, verapamil, insulin, medazepam, diazepam, butamirate, triamterene and hydrochlorothiazide].
Topics: Antitussive Agents; Diazepam; Humans; Hydrochlorothiazide; Insulin; Male; Medazepam; Medigoxin; Middle Aged; Phenylbutyrates; Poisoning; Suicide, Attempted; Triamterene; Verapamil | 1983 |
Diazepam induces tolerance in the isolated skin of Pleurodema thaul.
Topics: Animals; Anura; Calcium Channel Blockers; Delayed-Action Preparations; Diazepam; Drug Tolerance; Electrophysiology; GABA Modulators; In Vitro Techniques; Injections, Intraperitoneal; Membrane Potentials; Receptors, GABA-A; Skin; Verapamil | 1995 |
Signaling pathway downstream of GABAA receptor in the growth cone.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Animals, Newborn; Axons; Binding Sites; Calcium; Chlorides; Diazepam; Fetus; gamma-Aminobutyric Acid; GTPase-Activating Proteins; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Models, Neurological; Muscimol; Myristoylated Alanine-Rich C Kinase Substrate; Neurites; Picrotoxin; Prosencephalon; Proteins; Rats; Rats, Wistar; Receptors, GABA-A; Signal Transduction; Verapamil | 1996 |
Verapamil and acute dystonia.
Topics: Adult; Anti-Arrhythmia Agents; Diazepam; Dystonia; Female; Humans; Injections, Intravenous; Muscle Relaxants, Central; Tachycardia, Supraventricular; Verapamil | 1998 |
Sensitization by chronic diazepam treatment of A2A adenosine receptor-mediated relaxation in rat pulmonary artery.
Topics: Adenosine; Animals; Carrier Proteins; Diazepam; Dinucleoside Phosphates; Dipyridamole; Dose-Response Relationship, Drug; Female; Heart; Heart Atria; Muscle Relaxation; Phenethylamines; Pulmonary Artery; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; Thioinosine; Triazines; Triazoles; Verapamil | 1999 |
Cytoprotection and intracellular calcium.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Calmodulin; Cytoprotection; Diazepam; Epoprostenol; Female; Gastric Fundus; Gastric Mucosa; Models, Biological; Pyloric Antrum; Rats; Rats, Wistar; Trifluoperazine; Verapamil | 1999 |
Different transporters for tri-iodothyronine (T(3)) and thyroxine (T(4)) in the human choriocarcinoma cell line, JAR.
Topics: Analysis of Variance; Biological Transport; Calcium Channel Blockers; Choriocarcinoma; Cyclooxygenase Inhibitors; Diazepam; Female; GABA Modulators; Humans; Iodine Radioisotopes; Leucine; Meclofenamic Acid; Mefenamic Acid; Nifedipine; Nitrendipine; Phenylalanine; Phenytoin; Thyroxine; Triiodothyronine; Tryptophan; Tumor Cells, Cultured; Uterine Neoplasms; Verapamil | 2000 |
Negative inotropic effect of diazepam in isolated guinea pig heart.
Topics: Adjuvants, Anesthesia; Animals; Anti-Arrhythmia Agents; Calcium Channels; Depression, Chemical; Diazepam; Dose-Response Relationship, Drug; Female; Flumazenil; GABA Modulators; Guinea Pigs; Heart; In Vitro Techniques; Isoquinolines; Male; Membrane Potentials; Myocardial Contraction; Patch-Clamp Techniques; Verapamil | 2001 |
Diazepam stimulates migration and phagocytosis of human neutrophils: possible contribution of peripheral-type benzodiazepine receptors and intracellular calcium.
Topics: Calcium; Calcium Channel Blockers; Cells, Cultured; Chemotaxis, Leukocyte; Diazepam; Flow Cytometry; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Humans; In Vitro Techniques; Isoquinolines; Neutrophils; Phagocytosis; Receptors, GABA-A; Verapamil | 2001 |
Effects of L-type Ca2+ channel modulation on direct myocardial effects of diazepam and midazolam in adult rat ventricular myocytes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Calcium; Calcium Channels, L-Type; Diazepam; Dose-Response Relationship, Drug; Heart Ventricles; Midazolam; Myocytes, Cardiac; Rats; Sarcoplasmic Reticulum; Verapamil | 2006 |
Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy.
Topics: Amino Acid Sequence; Child; Chloride Channels; Diazepam; Electroencephalography; Epilepsy; Female; Genotype; HEK293 Cells; Humans; Insulin; Ion Channel Gating; Kinetics; Magnetic Resonance Imaging; Mutation; Phenotype; Protein Subunits; Receptors, GABA-A; Verapamil | 2019 |
Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Topics: Acetamides; Albuterol; Animals; Carbamates; Chromatography, Liquid; Diazepam; Diclofenac; Digitoxin; Humans; Itraconazole; Ketoprofen; Liver; Metabolic Clearance Rate; Mice; Mice, Transgenic; Naproxen; Pharmaceutical Preparations; Phenytoin; Piperidines; Pravastatin; Pyrimidines; Quinidine; Tandem Mass Spectrometry; Telmisartan; Terfenadine; Verapamil | 2020 |